

Serial No. 08/103,262

Page 2

5B3, 5B6, 5C2, 6D8, 6E10, 7F11, 7G11, 9E3, 10C1, [10D8, 10F6, 11G5,] 13H8, 14F12, and 15G7, which is covalently bound to a detectable marker or a water insoluble matrix.

- C 1
21. A composition suitable for administration to a patient consisting of a monoclonal antibody selected from the group consisting of monoclonal antibodies 5B3, 5B6, 5C2, 6D8, 6E10, 7F11, 7G11, 9E3, 10C1, [10D8, 10F6, 11G5,] 13H8, 14F12, and 15G7, in a sterile pharmaceutically acceptable vehicle.

Please add the following claims:

- 26. The antibody or epitope-binding fragment thereof of claim 19 that is monoclonal.
- C 2
27. The antibody or epitope-binding fragment thereof that is covalently bound to a detectable marker or a water insoluble matrix..
28. The monoclonal antibody or epitope binding fragment thereof of claim 26, selected from the group consisting of monoclonal antibodies 6E10, 13H8, and 6D8.
29. A hybridoma or cell culture comprising an antibody, or epitope-binding fragment thereof, which has the characteristics of a monoclonal antibody selected from the group consisting of 6E10, 13H8, and 6D8 produced by hybridomas with ATCC accession numbers CRL 10514, CRL 10510, and CRL 10513, respectively.
30. A hybridoma of claim 29 selected from the group consisting of hybridoma of ATCC accession numbers CRL 10514, CRL 10510, and CRL 10513.

REMARKS

Claims 19, 20 and 21 have been amended. Support for the amendments are found at page 43, lines 5-15, where the ATCC deposit information is provided as found in the Preliminary Amendment previously submitted, at page 39, line 30 to page 40, line 3, where detectably-labeled monoclonal antibodies and antibodies attached to supports are discussed, and at page 32, lines 3-7, page 36, lines 11-12, and page 37, lines 4-6, where epitope-binding nature of antibodies and antibody